ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe
Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe
📈 **POSITIVE** • High confidence analysis (88%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business